A Window of Opportunity to Control the Bacterial Pathogen Pseudomonas aeruginosa Combining Antibiotics and Phages

The evolution of antibiotic resistance in bacteria is a global concern and the use of bacteriophages alone or in combined therapies is attracting increasing attention as an alternative. Evolutionary theory predicts that the probability of bacterial resistance to both phages and antibiotics will be lower than to either separately, due for example to fitness costs or to trade-offs between phage resistance mechanisms and bacterial growth. In this study, we assess the population impacts of either individual or combined treatments of a bacteriophage and streptomycin on the nosocomial pathogen Pseudomonas aeruginosa. We show that combining phage and antibiotics substantially increases bacterial control compared to either separately, and that there is a specific time delay in antibiotic introduction independent of antibiotic dose, that minimizes both bacterial density and resistance to either antibiotics or phage. These results have implications for optimal combined therapeutic approaches.

[1]  Sylvain Moineau,et al.  Revenge of the phages: defeating bacterial defences , 2013, Nature Reviews Microbiology.

[2]  J. Blázquez,et al.  Antibiotics and antibiotic resistance: a bitter fight against evolution. , 2013, International journal of medical microbiology : IJMM.

[3]  M. Hochberg,et al.  Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1 , 2013, Evolutionary applications.

[4]  B. B. Finlay,et al.  The role of the immune system in governing host-microbe interactions in the intestine , 2013, Nature Immunology.

[5]  S. Abedon,et al.  Phage cocktails and the future of phage therapy. , 2013, Future microbiology.

[6]  S. Zinner,et al.  Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. , 2013, The Journal of antimicrobial chemotherapy.

[7]  R. López-Rojas,et al.  Emerging therapies for multidrug resistant Acinetobacter baumannii. , 2013, Trends in microbiology.

[8]  Heather K. Allen,et al.  Treatment, promotion, commotion: antibiotic alternatives in food-producing animals. , 2013, Trends in microbiology.

[9]  M. Hochberg,et al.  Evolutionary rescue in populations of Pseudomonas fluorescens across an antibiotic gradient , 2013, Evolutionary applications.

[10]  O. Kaltz,et al.  The probability of evolutionary rescue: towards a quantitative comparison between theory and evolution experiments , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.

[11]  A. Buckling,et al.  Effects of Sequential and Simultaneous Applications of Bacteriophages on Populations of Pseudomonas aeruginosa In Vitro and in Wax Moth Larvae , 2012, Applied and Environmental Microbiology.

[12]  A. Buckling,et al.  Introducing yesterday's phage therapy in today's medicine , 2012 .

[13]  M. Hochberg,et al.  Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage , 2012, Evolutionary applications.

[14]  S. West,et al.  Mechanisms of Pathogenesis, Infective Dose and Virulence in Human Parasites , 2012, PLoS pathogens.

[15]  A. Buckling,et al.  Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms , 2012, Evolutionary applications.

[16]  S. Gorman,et al.  Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy , 2011, The Journal of pharmacy and pharmacology.

[17]  M. Fischbach Combination therapies for combating antimicrobial resistance. , 2011, Current opinion in microbiology.

[18]  C. Fernandez-Prada,et al.  Bacteriophage-Resistant Mutants in Yersinia pestis: Identification of Phage Receptors and Attenuation for Mice , 2011, PloS one.

[19]  R. Cantón,et al.  Emergence and spread of antibiotic resistance following exposure to antibiotics. , 2011, FEMS microbiology reviews.

[20]  R. Hancock,et al.  Pseudomonas aeruginosa: all roads lead to resistance. , 2011, Trends in microbiology.

[21]  T. Day,et al.  The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy , 2011, Proceedings of the National Academy of Sciences.

[22]  R. MacLean,et al.  The Fitness Cost of Rifampicin Resistance in Pseudomonas aeruginosa Depends on Demand for RNA Polymerase , 2011, Genetics.

[23]  G. Dougan,et al.  Molecular and physiological analysis of three Pseudomonas aeruginosa phages belonging to the “N4-like viruses” , 2010, Virology.

[24]  J. Collins,et al.  How antibiotics kill bacteria: from targets to networks , 2010, Nature Reviews Microbiology.

[25]  B. Murray,et al.  Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. , 2009, The New England journal of medicine.

[26]  E. Änggård,et al.  A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic‐resistant Pseudomonas aeruginosa; a preliminary report of efficacy , 2009, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[27]  Roy Kishony,et al.  Drug interactions and the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.

[28]  R. MacLean,et al.  The cost of multiple drug resistance in Pseudomonas aeruginosa , 2009, Journal of evolutionary biology.

[29]  Timothy K Lu,et al.  Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy , 2009, Proceedings of the National Academy of Sciences.

[30]  I. Connerton,et al.  Quantitative Models of In Vitro Bacteriophage–Host Dynamics and Their Application to Phage Therapy , 2009, PLoS pathogens.

[31]  Remy Chait,et al.  Drug interactions modulate the potential for evolution of resistance , 2008, Proceedings of the National Academy of Sciences.

[32]  D. Hartl,et al.  Accelerated evolution of resistance in multidrug environments , 2008, Proceedings of the National Academy of Sciences.

[33]  J. Wierzbowski,et al.  Combination drugs, an emerging option for antibacterial therapy. , 2007, Trends in biotechnology.

[34]  G. Drusano,et al.  Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin , 2007, Antimicrobial Agents and Chemotherapy.

[35]  R. Kishony,et al.  Antibiotic interactions that select against resistance , 2007, Nature.

[36]  François Taddei,et al.  Viruses' Life History: Towards a Mechanistic Basis of a Trade-Off between Survival and Reproduction among Phages , 2006, PLoS biology.

[37]  A. Buckling,et al.  The effect of a bacteriophage on diversification of the opportunistic bacterial pathogen, Pseudomonas aeruginosa , 2005, Proceedings of the Royal Society B: Biological Sciences.

[38]  K. Poole Aminoglycoside Resistance in Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.

[39]  Frederick M. Ausubel,et al.  Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation , 2002, Nature.

[40]  Peter Sander,et al.  Mechanisms of Streptomycin Resistance: Selection of Mutations in the 16S rRNA Gene Conferring Resistance , 2001, Antimicrobial Agents and Chemotherapy.

[41]  M. Postelnick,et al.  The utility of aminoglycosides in an era of emerging drug resistance. , 1998, International journal of antimicrobial agents.

[42]  B. Levin,et al.  Phage Therapy Revisited: The Population Biology of a Bacterial Infection and Its Treatment with Bacteriophage and Antibiotics , 1996, The American Naturalist.

[43]  Rex Consortium,et al.  Heterogeneity of selection and the evolution of resistance. , 2013, Trends in ecology & evolution.

[44]  G. Darai,et al.  N4-like Viruses∗ , 2011 .